Clinical Trials on Recurrent Merkel Cell Carcinoma in Korea, Democratic People's Republic of

Total 949 results

Eisai Inc.
PharmaBio Development Inc.

Completed

E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck

Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck

United States, Korea, Republic of, Ukraine, United Kingdom
ETOP IBCSG Partners Foundation
Roche Pharma AG

Active, not recruiting

ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma (ABC-lung)

EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC

Singapore, Spain, Korea, Republic of, Switzerland, Germany
Hoffmann-La Roche

Completed

Treatment Registry of Alectinib in Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Korea

Non-Small Cell Lung Cancer

Korea, Republic of
AstraZeneca
Daiichi Sankyo

Recruiting

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer (TROPION-Lung14)

Non-small Cell Lung Cancer

Germany, Taiwan, Australia, China, Korea, Republic of
Novartis Pharmaceuticals

Completed

Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.

Non-small Cell Lung Cancer

Taiwan, Spain, Italy, United States, Korea, Republic of, France
Kartos Therapeutics, Inc.

Terminated

KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer

Small Cell Lung Carcinoma | Small-cell Lung Cancer | Small Cell Lung Cancer Extensive Stage | Small Cell Lung Cancer Recurrent

Germany, Spain, France, Australia, United States, Korea, Republic of, Hungary
Novartis Pharmaceuticals

Completed

A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies

Advanced Non-small Cell Lung Cancer

Spain, Canada, Germany, Korea, Republic of, Taiwan, United States, Japan, Netherlands, Singapore
Novartis Pharmaceuticals

Terminated

Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients

Squamous Non-small Cell Lung Cancer

Germany, Spain, Korea, Republic of, Belgium, Italy, United States, France, Sweden
AstraZeneca

Active, not recruiting

Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC

Non Small Cell Lung Cancer

Belgium, Korea, Republic of, Spain, United States, France
Flamingo Therapeutics NV

Recruiting

Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC (PEMDA-HN)

HNSCC

United States, Korea, Republic of
ETOP IBCSG Partners Foundation
Hoffmann-La Roche; AstraZeneca

Active, not recruiting

Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M (BOOSTER) (BOOSTER)

Non Small Cell Lung Cancer Metastatic

Ireland, Singapore, Spain, Switzerland, Korea, Republic of, Netherlands
Novartis Pharmaceuticals

Recruiting

Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

United States, Korea, Republic of, Spain, Japan, Germany, Switzerland
Hoffmann-La Roche

Completed

A Study of Tarceva (Erlotinib) in Combination With Platinum Based Chemotherapy in Patients With Non-Small Cell Lung Cancer.

Non-Small Cell Lung Cancer

Hong Kong, Taiwan, Philippines, China, Thailand, Indonesia, Australia, Korea, Republic of
X4 Pharmaceuticals

Completed

Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma

United States, Korea, Republic of
Eli Lilly and Company

Completed

A Study of Advanced or Metastatic Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

United States, Taiwan, Italy, Korea, Republic of
Hoffmann-La Roche

Recruiting

A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)

Squamous Cell Carcinoma of the Head and Neck

Korea, Republic of, United States, France, Australia, Israel, Spain, United Kingdom, Switzerland
AstraZeneca

Completed

Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC

Non Small Cell Lung Cancer

Korea, Republic of, Taiwan, United Kingdom, Spain, United States, Netherlands
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer

China, Korea, Republic of, Thailand
AstraZeneca

Completed

SUPREME-HN A Retrospective Cohort Study of PD-L1 in Recurrent and Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) (SUPREME-HN)

Squamous Cell Carcinoma of the Head and Neck

United States, Italy, Korea, Republic of, Spain, Greece, Germany, Japan
Exelixis

Recruiting

Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (STELLAR-305)

Head and Neck Squamous Cell Carcinoma

United States, Belgium, Bulgaria, France, Italy, Korea, Republic of, Romania, Slovakia
Samsung Bioepis Co., Ltd.

Recruiting

A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based Chemotherapy

Non-small Cell Lung Cancer Stage IIIA | Non-small Cell Lung Cancer Stage II

Korea, Republic of, Poland, Spain, Turkey
Yuhan Corporation
The Korean Academy of Tuberculosis and Respiratory Diseases

Active, not recruiting

Korean Registry of Non-Small Cell Lung Cancer Patients With EGFR Mutation

NSCLC

Korea, Republic of
AstraZeneca

Active, not recruiting

Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia Pacific (AURA17)

Non-Small Cell Lung Cancer

Korea, Republic of, China, Australia
R-Pharm
Data Management 365; Exacte Labs LLC; Federal State Budgetary Institution "NMIC... and other collaborators

Active, not recruiting

Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms

Head and Neck Squamous Cell Carcinoma | Skin Melanoma | Squamous Non-small-cell Lung Cancer

Russian Federation
Novartis Pharmaceuticals

Terminated

Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma (CATChEz)

Carcinoma, Renal Cell

Australia, Korea, Republic of
National Cancer Centre, Singapore
National Medical Research Council (NMRC), Singapore; Innogene Kalbiotech Pte...

Active, not recruiting

Study of Post-Op Adjuvant Concurrent Chemo-RT With or Without Nimotuzumab for Head & Neck Cancer

Carcinoma, Squamous Cell of Head and Neck

Philippines, Thailand, Korea, Republic of, Australia, Taiwan, India, Saudi Arabia, Singapore, South Africa, Egypt, Cuba, Indonesia, Malaysia
Novartis Pharmaceuticals

Completed

A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.

Non-small-cell Lung Cancer

Canada, France, Spain, Netherlands, Singapore, Germany, Korea, Republic of, Turkey, United States, Norway
Novartis Pharmaceuticals

Completed

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma

United States, Spain, Taiwan, Germany, Netherlands, United Kingdom, Korea, Republic of
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Mucinous... and other conditions

United States, Korea, Republic of, Japan
Incyte Corporation

Terminated

Study of INCB086550 in Select Solid Tumors

Melanoma | Renal Cell Carcinoma | Hepatocellular Carcinoma | Non Small Cell Lung Cancer | Urothelial Cancer

Korea, Republic of, Bulgaria, Hungary, Taiwan, Ukraine
AstraZeneca

Completed

Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)

Advanced Non Small Cell Lung Cancer | Advanced (Inoperable) Non Small Cell Lung Cancer

Belgium, United States, Korea, Republic of, Taiwan, United Kingdom, Netherlands
AstraZeneca

Completed

Randomized Study Of CP-675,206 or Best Supportive Care Immediately After Platinum-Based Therapy For Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-small-cell Lung

United States, Canada, Korea, Republic of, United Kingdom, Czech Republic
Ascendis Pharma Oncology Division A/S

Recruiting

A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or Chemotherapy or TransCon TLR7/8 Agonist in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies (IL Believe)

Advanced Solid Tumor | Metastatic Solid Tumor | Platinum-resistant Ovarian Cancer | Locally Advanced Solid Tumor | Post Anti-PD-1 Melanoma | 2L+ Cervical Cancer | Neoadjuvant Melanoma | Neoadjuvant Non-Small Cell Lung Cancer | Post Anti-PD-(L)1 Non-Small Cell Lung Cancer | Post Anti-PD-(L)1 Small Cell...

United States, Australia, Korea, Republic of
Coherus Biosciences, Inc.
Merck Sharp & Dohme LLC

Recruiting

Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

Clear Cell Renal Cell Carcinoma | Hepatocellular Carcinoma | Advanced Solid Tumor | Non-small Cell Lung Cancer

Korea, Republic of, United States, Singapore
AbbVie

Recruiting

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Budigalimab

Non-Small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma

United States, Japan, Israel, Korea, Republic of
MitoImmune Therapeutics

Recruiting

MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients (MIT-001)

Head and Neck Squamous Cell Carcinoma | Oral Mucositis

Korea, Republic of, United States
Arbutus Biopharma Corporation

Completed

Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma | Hepatoma | Liver Cancer, Adult | Liver Cell Carcinoma, Adult

United States, Taiwan, Singapore, China, Canada, Korea, Republic of
Eli Lilly and Company

Completed

A Study for Participants With Small-Cell Lung Cancer

Small Cell Lung Cancer

United States, Korea, Republic of, Romania
SillaJen, Inc.
Regeneron Pharmaceuticals

Active, not recruiting

A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma

Renal Cell Carcinoma

United States, Australia, Korea, Republic of
BeiGene

Active, not recruiting

A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Esophageal Cancer | Esophageal Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma by AJCC V8 Stage

China, Thailand, Korea, Republic of
AstraZeneca

Completed

Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer (EAGLE)

Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN

United States, France, Italy, Spain, Belgium, Czechia, Romania, Taiwan, Korea, Republic of, Brazil, Hungary, Japan, Russian Federation, Australia, Germany, Israel, Serbia, Bulgaria, Ukraine, Argentina, Poland, Chile, Croatia, Georgia
Takeda

Recruiting

A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer

Colorectal Cancer | Non-small Cell Lung Cancer (NSCLC) | Squamous Cell Cancer of Head and Neck (SCCHN)

Korea, Republic of, United States, Australia
Sanofi
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204)

Squamous Cell Carcinoma of Head and Neck

Spain, Italy, United States, Chile, France, Argentina, Canada, Germany, Korea, Republic of, Netherlands, Taiwan
Hoffmann-La Roche

Completed

A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

Non-Squamous Non-Small Cell Lung Cancer

China, Hong Kong, Taiwan, Philippines, Thailand, Korea, Republic of, Indonesia
Pfizer

Terminated

Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)

Non-Small Cell Lung Cancer

United States, Korea, Republic of, Australia, Japan
Merck Sharp & Dohme LLC

Active, not recruiting

A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)

Urothelial Carcinoma

Australia, United States, Chile, Denmark, Israel, Korea, Republic of, Spain
MedImmune LLC

Active, not recruiting

Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study

Carcinoma, Non-Small-Cell Lung

United States, Korea, Republic of, Taiwan
Kura Oncology, Inc.

Completed

Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations

Thyroid Cancer | Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | HRAS Mutant Tumor | Other Squamous Cell Carcinoma (SCC) With HRAS Mutant Tumor

Spain, United States, Korea, Republic of, France, Belgium, Germany, Greece, Italy, Netherlands, United Kingdom
Genentech, Inc.

Terminated

A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy

Urothelial Carcinoma

Korea, Republic of, United States, Canada, United Kingdom, Belgium
Daiichi Sankyo, Inc.

Completed

Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung Cancer

Advanced Non-small Cell Lung Cancer (NSCLC)

Korea, Republic of, United States, India, Germany

Clinical Trials on Recurrent Merkel Cell Carcinoma in Korea, Democratic People's Republic of

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Spain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations